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Purpose: as the use of accelerated partial breast irradiation (APBI) becomes more widely used it
is important to deﬁne and characterize the possible toxicities encountered with this type of
therapy to help understand how to prevent these toxicities in the future.
Methods and materials: a 60-year-old woman was treated with APBI using external beam radiation.
Three weeks post radiation therapy, she was given a cycle of docetaxel and cyclophosphamide.
Within 3 weeks of chemotherapy she developed a radiation dermatitis ulceration in her right axilla
and tail of her right breast. Little data exists regarding the association between the actual volume of
skin irradiated during external beam APBI and the development of skin toxicity such as RRD,
therefore we analyzed the volume of skin getting various prescription doses in our patient and
compared them to 30 similar breast cancer patients treated with external beam radiation APBI at the
same institution.
Results: our patient's volume of skin getting 100%, 90% and 80% of the prescription dose was below
the mean for all three doses when compared to all other patient's treated similarly at our institution.
Conclusions: we present an example of radiation recall dermatitis in a patient receiving APBI with
external beam radiation followed by chemotherapy. In our case, volume of skin irradiated did not
appear to be associated with the development of RRD, therefore other factors may have led to her
development of this rare skin reaction.
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Radiation recall dermatitis (RRD) is an acute inﬂammatory
condition of the skin in a previously irradiated area,
generally triggered by administration of certain agents,
such as antineoplastic drugs. Several cases of RRD haveen access article under the CC BY-NC-ND license
C. Miller et al.34been described using numerous chemotherapy agents and
various methods of radiation delivery, but here we des-
cribe a case of radiation recall in a patient who received
docetaxel and cyclophosphamide chemotherapy following
accelerated partial breast irradiation (APBI) with external
beam radiation.2. Case report
A 60-year-old black female presented with a new suspicious
mass in the posterior lateral aspect of the right breast found
on screening mammogram on March 17, 2012. Ultrasound
guided core biopsy revealed an inﬁltrating lobular carcinoma
with focal LCIS with ductal extension. She underwent right
breast lumpectomy and sentinel lymph node biopsy on April 5,
2012. Final pathology revealed a 1.2 cm lobular carcinoma
with negative margins and one benign sentinel lymph node.
Final staging was reported as pT1cN0M0 (stage IA). The tumor
was estrogen receptor and progesterone receptor positive and
Her2neu not overexpressed. Post-operatively she was placed
on trimethoprim/sulfamethoxazole for redness noted at the
incision site, with spontaneous resolution of symptoms.
She was next treated with APBI via external beam
radiation beginning on May 10, 2012. The seroma and clips
were treated in 10 fractions over the course of ﬁve days.
She received a total of 38.5 Gy over those ﬁve days with
treatment twice a day of 3.85 Gy per dose. Her course of
radiation treatment concluded on May 16, 2012.
On June 7, 2012, exactly 3 weeks post-radiation therapy,
chemotherapy was initiated, consisting of docetaxel 75 mg/
m2 and cyclophosphamide 600 mg/m2. When she presented
for her second course of chemotherapy on June 21, 2012 it
was noted that the patient had developed a 2 2 cm2 area
of moderate erythema with edema and moist desquamation
her right axilla and tail of the right breast. The chemother-
apy was tentatively held at that time and the patient was
instructed to keep the area clean and apply duoderm until
healed. Cycle 2 was delayed for 6 weeks and was restarted
once the skin had healed to a wound measuring 5 mm in her
axillary fold. Following the second cycle of chemotherapy
the patient suffered from a recurrence of the RRD consisting
of desquamation and a non-healing wound in the right
axilla. At this time the patient's chemotherapy was switched
to weekly paclitaxel 80 mg/m2. One week after her ﬁrst
cycle of paclitaxel the 5 mm open wound in the right axilla
remained unchanged from before the therapy. In August
2012 she began to apply silver sulfadiazine to dress the area
with moist desquamation. She was continued on weekly
paclitaxel treatments, which she completed on September
27, 2012. The patient began aromatase inhibitor therapy on
October 15, 2012.
Our patient had a complicated course of healing from the
RRD. At her six month follow-up appointment in February
2013 she presented with right upper extremity and breast
lymphedema, which was treated with Flexitouch therapy
three times per week. On March 29, 2013 the patient
presented to the ofﬁce febrile, with her right breast warm,
erythematous and tender. She was placed on a course of
erythromycin with slight improvement. Two weeks later she
was placed on ciproﬂoxacin and rifampin with improvement
of the pain and swelling. She applied Aquaphor to the siteand also underwent physical therapy, psychological therapy
and lymphadema therapy for the dermatitis. The patient's
pain was so severe during this time she was placed on a pain
regimen, using 4 break-through tabs of 5 mg oxycodone
daily with twice daily 30 mg oxycodone ER for maintenance.
Patient received steroid injections in her right shoulder and
followed up with an orthopedic surgeon and a physical
therapist. In January 2013 patient was placed on pentoxifyl-
line and vitamin E in hopes of improving her right axillary
and right breast symptoms. The wound eventually healed
completely after 18 months and was an open ulceration for
at least a year of that time.3. Discussion
Our case demonstrates an example of RRD precipitated by
treatment with docetaxel and cyclophosphamide, following
the use of APBI with external beam radiation. There are
many proposed hypotheses for the development of RRD, but
there are currently no known predictive factors. These
hypotheses focus on vascular, epithelial stem cell inade-
quacy, and epithelial stem cell sensitivity of drug hypersen-
sitivity reactions as the mechanism for RRD [1]. Bostrom
et al. have proposed that the radiotherapy induces local
vascular permeability or a proliferative change that upon
exposure to certain drugs elicits the RRD by affecting the
subsequent pharmacokinetics of the drug [2]. Hellman and
Botnick have proposed that by irradiating the skin, that
region of epithelial stem cells becomes depleted and the
stem cell numbers never fully recover [3]. Seymour et al.
went on to add that although stem cells were present
following the radiotherapy, their ability to proliferate and
been permanently altered disabling them from performing
their normal function as a stem cell [4]. Based on the speed
of onset and drug speciﬁcity of RRD Cambridge and Price
propose that the mechanism is not based on the triggering
drug's cytotoxicity, but on idiosyncratic drug hypersensitiv-
ity reactions instead via non-immune activation of inﬂam-
matory pathways [1].
While the etiology of RRD still remains unknown, the
phenomenon is still relatively rare. Many recorded cases
have begun to piece together some common denominators.
Many reactions have been documented with cytotoxics, and
several chemotherapeutic drugs in particular have been
implemented in this type of reaction, including adriamycin,
bleomycin, docetaxel, 5-ﬂuorouracil, gemcitabine, pacli-
taxel, vinblastine, and tamoxifen. The majority of breast
cancer patients receiving conventional whole breast exter-
nal beam irradiation receive their radiation after che-
motherapy. However, unlike whole breast irradiation, APBI
is typically given before chemotherapy, and the appropriate
amount of spacing between treatments has been brought
into question. Multiple studies have also focused on the
time course that occurs between administration of che-
motherapy and radiation. It has been reported that RRD is
more prevalent, with higher rates of reactions, in those
receiving chemotherapy within 3 weeks of radiation with
increasing prevalence as the interval shortens [5]. A case
documented with docetaxel administration after APBI with
electronic brachytherapy, found that in patients receiving
electronic brachytherapy, a minimum surface-to-skin distance
Figure 1
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needs to be established [6]. However, the idea must also be
presented that this case could have been the result of a
delayed skin reaction as opposed to a true radiation recall
reaction. A study performed at the Curie Institute showed that
the use of hypofractionation in breast radiotherapy showed
excellent initial skin tolerance, with the development of skin
reactions up to two weeks following the completion of
radiation treatment [7]. This could be a confounding issue in
the case we have presented here.
In addition, this case brings about the possibility that RRD
may be associated with predisposing risk factors. Our
patient had many co-morbid conditions and also a skin
hypersensitivity that may have led to her to developing a
radiation recall reaction following the administration of her
chemotherapy regimen. Our patient has a long-standing
history of type II diabetes, which was frequently uncon-
trolled during her course of the chemotherapy. Uncontrolled
diabetes promotes poor wound healing, which may have
contributed to the severity and prolonged course of healing
seen in her case. Also, due to our patient's morbid obesity
(BMI of 58.72 kg/m2), while the ratio of target volume tooverall breast tissue was low, the actual volume treated was
quite high (3664 cm3 total breast tissue, 577 cm3 target
volume, and 861 cm3 receiving 95% of prescription dose).
Studies have shown that body mass index and associated
increases in dose inhomogeneity appear to increase the risk
of moist desquamation following breast irradiation. The
relative risk of skin toxicity with a severity of any grade was
found to be 2.86 times higher in obese patient [8]. Our
patient also has a history of eczema, a type 1 hypersensi-
tivity, which may also play a role in patient's experiencing a
radiation reaction. Cases have been documented with
patient's of known skin allergens, such as latex allergies,
developing RRD [9]. A prior study had shown that after
discontinuation of the inducing drug and after allowing for
complete healing of the reaction site, they were able to
restart the drug and treatment resumed without further
recurrence of the dermatitis [10].
Very little data exists regarding the actual volume of skin
(deﬁned as the tissue within 5 mm of the external surface)
irradiated during external beam APBI and the development
of skin toxicity such as RRD. To examine this further, we
analyzed the volume of skin getting 100%, 90%, and 80% of
the prescription dose respectively in our patient. We then
compared this to the values obtained from 30 similar breast
cancer patients treated with external beam APBI at the
same institution (Figure 1). As can be seen, our patient's
volume of skin being irradiated lies below the mean for all
three dose levels. Although this is only one case, this may
indicate that the development of RRD following external
beam APBI is not related to volume of skin irradiated.
Further study would be needed to better deﬁne this.
4. Conclusion
The case we present here is an example of radiation recall
dermatitis following APBI with external beam radiation. Our
reaction occurred in response to chemotherapy with doc-
etaxel and cyclophosphamide delivered three weeks post
radiation, this ultimately required a change in therapy to
paclitaxel in order to successfully complete the treatments.
A change in treatment regimen can be detrimental to a
patient due to the delay in treatment it creates. While a
longer time interval between APBI and the initiation of
chemotherapy may have helped, it is unclear at this time if
this is the sole mechanism behind the reaction. At least in
our patient's case, volume of skin irradiated did not appear
to be associated with the development of RRD. While our
patient's multiple co-morbid conditions may also have
contributed to her skin reaction, further study in this area
is warranted to help prevent this signiﬁcant toxicity.
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